Description

VITA B12 Injection, also known as Vita-B12®, is a specialized pharmaceutical product developed by Amidpharm Mercury (Australia) Pty Ltd. This formulation contains hydroxocobalamin acetate at a concentration of 1 mg/mL, designed for intramuscular administration. It is presented as a clear, pale red solution, packaged in Type I glass ampoules with each carton containing three 1 mL ampoules.

Indications

This injection is primarily indicated for the prevention and treatment of anaemias associated with vitamin B12 deficiency, including pernicious anaemia and other macrocytic anaemias. It is also used in the management of certain optic neuropathies, nitrous oxide neurotoxicity, and at higher doses, cyanide toxicity.

Administration

• Method: Intramuscular injection by a healthcare professional.
• Dosage: Determined by a doctor based on specific patient needs.
• Note: Not intended for intravenous use.

Contraindications

VITA B12 Injection should not be used by individuals with known hypersensitivity to hydroxocobalamin, cobalt, or any of its inactive ingredients. It is also not recommended for treating megaloblastic anaemia during pregnancy.

Precautions

• Caution is advised for patients with spinal cord disease or folate-deficient megaloblastic anaemia.
• Use during pregnancy and breastfeeding should be carefully considered.
• The product is intended for single use only.

Drug Interactions

Potential interactions may occur with medications such as chloramphenicol, oral contraceptives, folic acid, H2 receptor antagonists, metformin, and proton pump inhibitors like omeprazole.

Side Effects

Common side effects include:

• Diarrhoea
• Nausea
• Vomiting
• Headache
• Dizziness
• Injection site reactions

Rare but serious side effects may involve allergic reactions, changes in heart rate, and anaphylactic shock.

Storage

• Store below 25°C.
• Protect from light.
• Keep in original packaging until use.
• Use immediately after opening.

Additional Information

VITA B12 Injection is not classified as a controlled substance in Australia and is registered under ARTG 172663. Recent supply disruptions have been reported, with an expected resolution in the first quarter of 2024. The product listing was last updated on 18 June 2025.